Adrenergic receptor: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 45: | Line 45: | ||
==Genetic polymorphisms== | ==Genetic polymorphisms== | ||
[[Genetic polymorphism]]s of beta-1 (ADRB1) may affect the response to [[adrenergic beta-antagonist]] treatment of [[heart failure]].<ref>{{OMIM|109630}}</ref> | [[Genetic polymorphism]]s of beta-1 (ADRB1) may affect the response to [[adrenergic beta-antagonist]] treatment of [[heart failure]].<ref>{{OMIM|109630}}</ref> | ||
[[Genetic polymorphism]]s of beta-2 (ADRB2), specifically the c.79C>G and c.46G>A [[single-nucleotide polymorphism]]s, may affect the response to adrenergic beta-antagonist treatment of [[acute coronary syndrome]].<ref name="pmid16189366">{{cite journal| author=Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA| title=Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. | journal=JAMA | year= 2005 | volume= 294 | issue= 12 | pages= 1526-33 | pmid=16189366 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&[email protected]&retmode=ref&cmd=prlinks&id=16189366 | doi=10.1001/jama.294.12.1526 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | |||
[[Genetic polymorphism]]s of alpha-2C (ADRA2C) may affect the response to [[adrenergic beta-antagonist]] treatment of [[heart failure]].<ref>{{OMIM|104250}}</ref> | [[Genetic polymorphism]]s of alpha-2C (ADRA2C) may affect the response to [[adrenergic beta-antagonist]] treatment of [[heart failure]].<ref>{{OMIM|104250}}</ref> | ||
Revision as of 16:35, 4 December 2009
In biochemistry, adrenergic receptors are cell surface receptors of the G-protein-coupled receptor type that are in the sympathetic nervous system and are "cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction."[1]
Classification
alpha-Adrenergic Receptors
Phenoxybenzamine is a non-selective antagonist of both alpha-1 receptors and alpha-2 receptors.
alpha-1 receptors
Alpha-1 adrenergic receptors are a "subclass of alpha-adrenergic receptors (Receptors, Adrenergic, alpha). Alpha-1 Adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist phenylephrine and the antagonist prazosin. They are widespread, with clinically important concentrations in the liver, the heart, vascular, intestinal, and genitourinary smooth muscle, and the central and peripheral nervous systems."[2] Their functions include vasoconstriction.
Agonists, such as phenylephrine, are used to treat nasal congestion by causing vasoconstriction. Midodrine is an agonist that is used for orthostatic hypotension and hepatorenal syndrome.
Antagonists, such as prazosin, are used to treat hypertension by blocking vasoconstriction.
alpha-2 receptors
Alpha-2 adrenergic receptors are a "subclass of alpha-adrenergic receptors (Receptors, adrenergic, alpha). Alpha-2 Adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist clonidine and the antagonist yohimbine. They are found on pancreatic beta cells, platelets, and vascular smooth muscle, as well as both pre- and postsynaptically in the central and peripheral nervous systems."[3]
Genetic polymorphisms of alpha-2C (ADRA2C) may affect the response to adrenergic beta-antagonist treatment of heart failure.[4]
Agonists, such as clonidine, are used to treat hypertension.
Antagonists, such as yohimbine, are used to treat erectile dysfunction.
beta-Adrenergic Receptors
beta-1 receptors
Beta-1 adrenergic receptors are a "subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-1 adrenergic receptors are equally sensitive to epinephrine and norepinephrine and bind the agonist dobutamine and the antagonist metoprolol with high affinity. They are found in the heart, juxtaglomerular cells, and in the central and peripheral nervous systems."[5]
Adrenergic beta-agonists such as dobutamine, are used to treat circulatory shock by increasing heart contractility.
Adrenergic beta-antagonists that are selective for the beta-1 receptor such as metoprolol and atenolol, are used to treat hypertension and tachyarrythmias.
Abnormal genetic polymorphism of the beta-1 receptor may affect responses to adrenergic beta-antagonists in the treatment of heart failure[6] and in preventing cardiac complications during perioperative care.[7]
beta-2 receptors
Beta-2 adrenergic receptors are a "subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-2 Adrenergic receptors are more sensitive to epinephrine than to norepinephrine and have a high affinity for the agonist terbutaline. They are widespread, with clinically important roles in skeletal muscle, liver, and vascular, bronchial, gastrointestinal, and genitourinary smooth muscle."[8] Their functions include vasodilation.
Adrenergic beta-agonists, such as terbutaline, are used to treat asthma by preventing bronchoconstriction.
Genetic polymorphisms of beta-2 (ADRB2), specifically the c.79C>G and c.46G>A single-nucleotide polymorphisms, may affect the response to adrenergic beta-antagonist treatment of acute coronary syndrome.[9]
beta-3 receptors
Beta-3 adrenergic receptors are a "subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-3 adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown adipocytes and are involved in modulating energy metabolism and thermogenesis."[10]
Genetic polymorphisms
Genetic polymorphisms of beta-1 (ADRB1) may affect the response to adrenergic beta-antagonist treatment of heart failure.[11]
Genetic polymorphisms of beta-2 (ADRB2), specifically the c.79C>G and c.46G>A single-nucleotide polymorphisms, may affect the response to adrenergic beta-antagonist treatment of acute coronary syndrome.[9]
Genetic polymorphisms of alpha-2C (ADRA2C) may affect the response to adrenergic beta-antagonist treatment of heart failure.[12]
References
- ↑ Anonymous. Receptors, Adrenergic. National Library of Medicine. Retrieved on 2008-01-21.
- ↑ Anonymous. Receptors, Adrenergic, alpha-1. National Library of Medicine. Retrieved on 2008-01-16.
- ↑ Anonymous. Receptors, Adrenergic, alpha-2. National Library of Medicine. Retrieved on 2008-01-16.
- ↑ Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 104250. World Wide Web URL: http://omim.org/.
- ↑ Anonymous. Receptors, Adrenergic, beta-1. National Library of Medicine. Retrieved on 2008-01-16.
- ↑ Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 109630. World Wide Web URL: http://omim.org/.
- ↑ Zaugg M, Bestmann L, Wacker J, et al. (July 2007). "Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up". Anesthesiology 107 (1): 33–44. DOI:10.1097/01.anes.0000267530.62344.a4. PMID 17585213. Research Blogging.
- ↑ Anonymous. Receptors, Adrenergic, beta-2. National Library of Medicine. Retrieved on 2008-01-16.
- ↑ 9.0 9.1 Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA (2005). "Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.". JAMA 294 (12): 1526-33. DOI:10.1001/jama.294.12.1526. PMID 16189366. Research Blogging.
- ↑ Anonymous. Receptors, Adrenergic, beta-3. National Library of Medicine. Retrieved on 2008-01-16.
- ↑ Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 109630. World Wide Web URL: http://omim.org/.
- ↑ Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 104250. World Wide Web URL: http://omim.org/.